ARGX vs BIIB
Argenx SE and Biogen Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | ARGX | BIIB |
|---|---|---|
| Revenue | $4.2B | $9.9B |
| Net income | $1.3B | $1.3B |
| Gross margin | 89.1% | 75.7% |
| Net margin | 31.1% | 13.1% |
| Return on equity | 20.2% | 7.4% |
| Diluted EPS | $19.57 | $8.79 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $679.0M | $2.1B |
| Equity | · | · |
| Net debt / equity | · | 0.18× |
| Current ratio | 5.23× | 2.68× |
| Revenue CAGR 5y | 151.5% | −6.0% |
| Profit CAGR 5y | · | −20.2% |
BIIB bills 2.4× the revenue of ARGX, and ARGX keeps more of each dollar of revenue as profit (31.1% against 13.1%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | ARGX | BIIB |
|---|---|---|
| FY2025 | $4.2B | $9.9B |
| FY2024 | $2.2B | $9.7B |
| FY2023 | $1.2B | $9.8B |
| FY2022 | $400.7M | $10.2B |
| FY2021 | $497.3M | $11.0B |
| FY2020 | $41.2M | $13.4B |
| FY2019 | $78.5M | $14.4B |
| FY2018 | · | $13.5B |
| FY2017 | · | $12.3B |
| FY2016 | · | $11.4B |
Bottom line
| Fiscal year | ARGX | BIIB |
|---|---|---|
| FY2025 | $1.3B | $1.3B |
| FY2024 | $833.0M | $1.6B |
| FY2023 | $-295.1M | $1.2B |
| FY2022 | $-709.6M | $3.0B |
| FY2021 | $-408.3M | $1.6B |
| FY2020 | $-608.5M | $4.0B |
| FY2019 | $-181.2M | $5.9B |
| FY2018 | · | $4.4B |
| FY2017 | · | $2.5B |
| FY2016 | · | $3.7B |
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$5,739,284,000 | BIIB |
| FY2024 | −$7,490,017,000 | BIIB |
| FY2023 | −$8,644,817,000 | BIIB |
| FY2022 | −$9,772,680,000 | BIIB |
| FY2021 | −$10,484,423,000 | BIIB |
| FY2020 | −$13,403,357,000 | BIIB |
| FY2019 | −$14,299,438,000 | BIIB |
BIIB has reported the higher revenue in every one of these 7 fiscal years. The gap has narrowed since the earliest year compared.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +18.1 pp | ARGX |
| FY2024 | +21.2 pp | ARGX |
| FY2023 | −36.6 pp | BIIB |
| FY2022 | −206.2 pp | BIIB |
| FY2021 | −97.8 pp | BIIB |
| FY2019 | −271.9 pp | BIIB |
| FY2018 | −343.5 pp | BIIB |
| FY2017 | −98.9 pp | BIIB |
| FY2016 | −177.6 pp | BIIB |
| FY2015 | −256.8 pp | BIIB |
The higher net margin has changed hands between ARGX and BIIB over this period.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ARGX's net margin has been more volatile than BIIB's over the 10 comparable fiscal years — 111.0 percentage points of standard deviation against 9.7.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between ARGX and BIIB over these 10 fiscal years — ARGX led in 2 and BIIB in 8.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ARGX's return on equity has been more volatile than BIIB's over the 11 comparable fiscal years — 20.5 percentage points of standard deviation against 12.3.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between ARGX and BIIB over these 11 fiscal years — ARGX led in 2 and BIIB in 9.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.